Trending...
- Citadel Credit Union's Business Banking Team Ready for August Launch
- Pennsylvania: Gov. Wolf Reacts to Dismantling of Roe v. Wade: "Elections Matter"
- REVIVV® Hair Growth Serum & Maskād® Post Procedure Face Masks by WETHRIVV™ Exhibit in Las Vegas
BERWYN, Pa.--(BUSINESS WIRE)--Amring Pharmaceuticals Inc. (Amring), a niche generic and brand pharmaceutical company, announced today that it has received FDA approval for generic Timolol Maleate Ophthalmic Solution, USP 0.5%, 60 pack of 0.3mL unit dose vials (AT3 rated generic equivalent of Timoptic® in Ocudose®) and has begun commercialization activities.
Preservative-free Timolol Maleate Ophthalmic Solution, USP is supplied in single-dose vials, as a sterile, isotonic, buffered, aqueous solution of timolol maleate and is indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Preservative-free Timolol Maleate Ophthalmic Solution, USP in the unit dose vial may be used when a patient is sensitive to:
"We are pleased to have added Timolol Maleate Ophthalmic Solution, USP to our generics portfolio," stated Daniel Carbery, President and CEO of Amring. "We are continuing to realize the benefits of this portfolio addition and to serving our patients and customers with high quality and affordable medicines."
More on The PennZone
About Amring Pharmaceuticals Inc.
Amring Pharmaceuticals is a privately held pharmaceutical company that provides niche generics and value-driven brands to the market. The company is a subsidiary of a privately held global specialty pharmaceutical company based in the Netherlands. Amring is partnered with well-established global biopharmaceutical companies and is uniquely positioned to leverage its expertise in bringing biotechnology derived medicines, sterile manufacturing and other state-of-the-art technologies to the marketplace.
Safe Harbor
This press release contains forward-looking statements, including, without limitation, statements related to Amring's business developments and the implementation of Amring's strategic initiatives. Because these statements reflect Amring's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties that could cause actual developments and results to differ materially from Amring's expectations. These factors include, but are not limited to, general market conditions, regulatory trends, changes in the financial conditions of third parties dealing with Amring, and other factors that could affect Amring's business and financial performance. Amring does not assume any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
More on The PennZone
Contacts
Amring Pharmaceuticals Inc.
Marina Volin, Esq.
VP, General Counsel
610-285-7137
Marina.volin@amringpharma.com
Preservative-free Timolol Maleate Ophthalmic Solution, USP is supplied in single-dose vials, as a sterile, isotonic, buffered, aqueous solution of timolol maleate and is indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Preservative-free Timolol Maleate Ophthalmic Solution, USP in the unit dose vial may be used when a patient is sensitive to:
- the preservative in Timolol Maleate Ophthalmic Solution, USP,
- benzalkonium chloride, or
- when the use of a preservative-free topical medication is advisable.
"We are pleased to have added Timolol Maleate Ophthalmic Solution, USP to our generics portfolio," stated Daniel Carbery, President and CEO of Amring. "We are continuing to realize the benefits of this portfolio addition and to serving our patients and customers with high quality and affordable medicines."
More on The PennZone
- High-Quality and Affordable Braces in Springfield Available from Exeter Orthodontics
- Southampton Dentures from DICE Dental Start at Only $499
- Always Ontime: Chaos City - Super Hero Graphic Novel with Neal Adams Cover Launches from Panopolis Metaverse
- Kelusky, Dietrich, Dawick, Gregoire, Lyle & Jeremy Thompson Nab Honors As NLL Opens Awards
- New Hampshire Becomes the 15th State to Require Personal Finance as a Core Academic Subject
About Amring Pharmaceuticals Inc.
Amring Pharmaceuticals is a privately held pharmaceutical company that provides niche generics and value-driven brands to the market. The company is a subsidiary of a privately held global specialty pharmaceutical company based in the Netherlands. Amring is partnered with well-established global biopharmaceutical companies and is uniquely positioned to leverage its expertise in bringing biotechnology derived medicines, sterile manufacturing and other state-of-the-art technologies to the marketplace.
Safe Harbor
This press release contains forward-looking statements, including, without limitation, statements related to Amring's business developments and the implementation of Amring's strategic initiatives. Because these statements reflect Amring's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties that could cause actual developments and results to differ materially from Amring's expectations. These factors include, but are not limited to, general market conditions, regulatory trends, changes in the financial conditions of third parties dealing with Amring, and other factors that could affect Amring's business and financial performance. Amring does not assume any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
More on The PennZone
- Pennsylvania: Gov. Wolf Announces Federal Transit Administration Grant to Expand Access to Transportation Assistance Programs
- Virtual Workplace Platform Developer REACH Expands Executive Team, Positioning the Company to Drive International Growth
- Global Tax Management Launches GTM Training Institute to Address Tax Talent Gap
- Fulton Bank to Eliminate Consumer Non-Sufficient Funds and Extended Overdraft Fees
- Health Advisory: Protecting Yourself and Others from Monkeypox
Contacts
Amring Pharmaceuticals Inc.
Marina Volin, Esq.
VP, General Counsel
610-285-7137
Marina.volin@amringpharma.com
Filed Under: Business
0 Comments
Latest on The PennZone
- BIOLASE ANNOUNCES SUPPORT FOR PROJECT HOME
- SwanBio Presents Design of Innovative Natural History Study Aimed to Evolve Understanding of Adrenomyeloneuropathy and Inform Future Treatments
- Avion Medical Skin Centres to offer innovative treatment for non-melanoma skin cancer patients
- Launch of Def Leppard beauty collection creating Hysteria in the makeup industry
- Pennsylvania: Gov. Wolf Applauds President Biden's Signing of First Comprehensive Gun Violence Package in Decades
- Direct Purchaser Plaintiffs Announce Settlements in In Re Generic Pharmaceutical Pricing Antitrust Litigation.
- Pennsylvania Commissions Condemn Supreme Court Decision, Remain Committed to Protecting the Right to Choose
- Pennsylvania: Gov. Wolf Shares Relief with Congressional Passage of Bipartisan Safer Communities Act, Urges Continued Momentum for Safer Communities
- Statement Pursuant to Section 19(a) of the Investment Company Act of 1940: DEX
- Ismail Sirdah' Guide To Landing Event Sponsorships
- INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Yext, Inc. (YEXT) Investors
- Pennsylvania: Gov. Wolf Reacts to Dismantling of Roe v. Wade: "Elections Matter"
- Children's Shoe Brand joins Soles4Souls in Ukrainian Refugee Relief Efforts
- The Data Economics Company announces partnership with Incradia to release the ReVerse franchise on Lydion-based Game Development Platform
- iTech offers 60-days free trial on expEDIum Medical Billing® product
- Pennsylvania: Gov. Wolf Commends Bipartisan Effort to Combat Surging Gun Violence, Eager for U.S. House to Send Bipartisan Safer Communities Act to President Biden's Desk
- Completion of funding round brings Metaphysiks one step closer to embodying the Metaverse
- On Anniversary of Surfside Tragedy, New Book Coaches Residents to Identify Warning Signs
- Citadel Credit Union's Business Banking Team Ready for August Launch
- Is Woody Biomass Fuel Making a Comeback?